Meltzer HY (2013) Update on typical and atypical antipsychotic drugs
D., Petrillo, T., Semprini, E., et al
Horm Metab Res (2015) 47:70210.10.1055/s-0035-1548832 84 PyzikAGrywalskaEMatyjaszek-MatuszekBRolinskiJ

Risks listed by the department The advisory enumerates specific risks associated with unauthorized or counterfeit products, including: containing too much, too little, or none of the active ingredient [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] containing unlisted, dangerous or unknown ingredients [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] containing contaminants such as solvents, heavy metals, particles, or microbials [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] being poorly or incorrectly labelled, or improperly manufactured or stored [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized] Health Canada adds that unauthorized injectable products carry additional risks such as infections due to lack of sterility, allergic reactions, and other serious negative outcomes due to contamination, improper handling, or unsafe administration [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized]
